Arctigenin (AR) and its glycoside, arctiin, are two major active ingredients of Arctium lappa L (A lappa), a popular medicinal herb and health supplement frequently used in Asia. In the past several decades, bioactive components from A lappa have attracted the attention of researchers due to their promising therapeutic effects. In the current article, we aimed to provide an overview of the pharmacology of AR and arctiin, focusing on their anti-inflammatory effects, pharmacokinetics properties and clinical efficacies. Compared to acrtiin, AR was reported as the most potent bioactive component of A lappa in the majority of studies. AR exhibits potent anti-inflammatory activities by inhibiting inducible nitric oxide synthase (iNOS) via modulation of several cytokines. Due to its potent anti-inflammatory effects, AR may serve as a potential therapeutic compound against both acute inflammation and various chronic diseases. However, pharmacokinetic studies demonstrated the extensive glucuronidation and hydrolysis of AR in liver, intestine and plasma, which might hinder its in vivo and clinical efficacy after oral administration. Based on the reviewed pharmacological and pharmacokinetic characteristics of AR, further pharmacokinetic and pharmacodynamic studies of AR via alternative administration routes are suggested to promote its ability to serve as a therapeutic agent as well as an ideal bioactive marker for A lappa.
Introduction
Arctigenin (AR) (Figure 1 ), a phenylpropanoid dizbenzylbutyrolactone lignan, was first identified in Arctium lappa L (A lappa), a popular medicinal herb and health supplement frequently used for anti-influenza treatment in Asia, especially China, Korea and Japan. AR and its glycoside, arctiin, are listed as both the chemical marker compounds and major active ingredients of Fructus Arctii in Chinese Pharmacopeia [1] . In the past several decades, bioactive components from A lappa, especially AR, have attracted the attention of researchers due to their promising therapeutic effects on inflammation [2] [3] [4] , infection [5] [6] [7] , metabolic disorders [8] [9] [10] , and central nervous system dysfunctions [11] [12] [13] . AR and arctiin have been extensively studied for their anti-inflammatory effects in both in vitro and in vivo models. Inflammation is a series of protective responses of the body against exogenous pathogens and to repair tissue damage resulting from infection or trauma. Acute inflammation is characterized by vasodilatation, fluid exudation and neutrophil infiltration [14] . Severe inflammation can cause organ injury, shock and even death, presenting major management problems [14] . Furthermore, when the inflammatory response does not eradicate the primary stimulus, a chronic form of inflammation ensues and contributes to further tissue damage. A number of chronic diseases, including atherosclerosis, cancer, type II diabetes, and Alzheimer's disease, have a pathophysiologically important inflammatory component [15] . Therefore, developing novel compounds targeting the inflammatory response can be beneficial for the treatment of acute inflammation and infection, as well as many widespread chronic diseases. Studies on the pharmacology of AR and arctiin as natural compounds with significant anti-inflammatory effects may contribute to the development of novel anti-inflammatory therapeutics.
Pharmacokinetic profiles, including the absorption, distribution, metabolism and excretion properties, determine the efficacy and safety of a potential therapeutic. Extensive in vitro and in vivo studies have been conducted on AR and arctiin to elucidate their absorption, metabolite profiles, and plasma concentration profiles, as well as the mechanisms involved. The results of these studies provide comprehensive data on the pharmacokinetic properties of AR and arctiin, leading to further optimization strategies for the use of these natural compounds as potential anti-inflammatory therapeutics.
Although research interest in AR, arctiin and A lappa has been growing rapidly, there are few published review articles on their pharmacological characteristics. In the current article, we aim to provide an overview of the pharmacology of AR and arctiin, especially their anti-inflammatory effects, pharmacokinetics properties and clinical efficacy.
Distribution of AR and arctiin in plants AR and arctiin belong to the family of lignans, which is a class of phytoestrogens characterized by their dibenzylbutane skeleton. Lignans were first identified in plants and are believed to play a role in the construction of plant cell wall as the precursor of lignin. The contents of AR and arctiin, as well as the total lignans, were found to be the highest in the fruit of A lappa among all the plant parts [16] . AR and arctiin account for approximately 0.5%-2% (w/w) and 2%-10% (w/w) of the dry weight of the fruit, respectively, depending on place of origin, processing methods, and other factors [17, 18] . AR is regarded as marker compound in dozens of other medicinal herbs, probably due to its promising therapeutic activities [19, 20] . AR and arctiin have been identified in not only A lappa but also more than 38 other plant species, among which 71% belong to the Asteraceae family. Table 1 summarizes the distribution of AR and arctiin in different plant species from eight families, including Aspleniaceae, Asteraceae, Convolvulaceae, Linaceae, Oleaceae, Styracaceae, Taxacea, and Thymelaeaceae. In the family Asteraceae, Centaurea is a genus that includes many AR-and arctiin-containing plants, although the AR and arctiin contents are lower than that in A lappa. Fruits and seeds had high levels of AR and arctiin [2, 21] , while the other parts, such as flower, leaves, stem, and roots, had low levels ( Table 1) . As shown in Table 1 , many of these AR-and arctiin-containing plants are recorded as medical plants in their growing areas and are well-recognized for the treatment of diseases, such as rheumatic arthritis, inflammatory diseases, infection, and others.
Effect of AR and arctiin against inflammatory diseases Effect of AR and arctiin on acute inflammation and its mechanism
Multiple studies have found that A lappa exhibits antiinflammatory activities, which were attributed to AR in most research focusing on the traditional Chinese herb [22] [23] [24] . The anti-inflammatory effect and the reported mechanism of AR are summarized in Table 2 .
The anti-inflammatory effects of AR were demonstrated in [89] remedy, laxative, and emmenagogue in the Italian folk medicine, as well as abortifacient in North America. Asteraceae
Arctium lappa Fruit Arctiin (2%-10%), The roots are traditionally used to treat [2, 21, AR (0.5%-2%) diseases such as sore throat and infections [90] [91] [92] [93] Root Arctiin (0.04%) such as rashes, boils and various skin problems. Stem Arctiin (0.06%) The seed and fruits are used for skin conditions Flower Arctiin (0.05%), as well as in cold/flu formulae of traditional AR (0.05%) Chinese medicine.
Arctium tomentosum
Root Arctiin (0.68%) The root and leaf are used for therapy of [94] Seed Arctiin (10.3%), rheumatism and paraesthesia of skin in Xinjiang, AR (0.2%) China.
Carduus micropterus
Aerial parts Arctiin, AR No medical use has been reported for this species. [95] Centaurea affinis Aerial parts AR (0.007%) No use has been reported for specific species. [96] Centaurea americana Seed Arctiin (0.2%), Many species of the genus Centaurea have long [97] AR (0.015%) been used in traditional medicine to cure diabetes,
Centaurea arenaria
Whole plant Arctiin, AR diarrhoea, rheumatism, malaria, hypertension etc. [98] Centaurea cuneifolia whole plant AR [97, 99] Centaurea dealbata Fruit Arctiin, AR [100] Centaurea macrocephala Seed Arctiin (0.3%) [101] Centaurea nigra Seed Arctiin (0.3%), [102] AR (0.06%)
Centaurea phrygia
Flower AR [103] Centaurea ptosimopappa Aerial parts AR [104] Centaurea scabiosa Fruit AR [100] Centaurea sclerolepis Fruit Arctiin [97, 100] Centaurea scoparia Aerial parts AR [105] Centaurea schischkinii Seed Arctiin, AR [19, 96] Centaurea scoparia Aerial parts AR (0.004%) [106] Centaurea tweediei Aerial parts AR [97, 107] Cirsium oleraceum Fruit Arctiin (3.9%), No medical use has been reported for this species. [108] AR (0.1%) Cirsium palustre Fruit Arctiin (2.8%), No medical use has been reported for this species. [100] AR (0.07%)
Saussurea conica
Whole plant AR No medical use has been reported for this species. [109] Saussurea medusa Aerial part Arctiin, AR (0.7%) The aerial part has been used for the treatment of [55] rheumatoid diseases in Northwest China and Nepal.
Saussurea salicifolia
Aerial part Arctiin, AR The aerial part has been used to treat [110, 111] gynaecological diseases, hepatitis, and gallbladder disorder in Mongolian traditional medicine.
Saussurea involucrata
Seed Arctiin (0.24%) No medical use has been reported for this species. [112] Onopordum cynarocephalum Aerial part AR A decoction or a tea of the whole plant is used in [113] folk medicine for digestion, cough sedating, and in biliary diseases in Lebanon. The decoction or infusion of flowering tops is used for the alleged treatment of malarial fever and for washing exanthematic skin.
Onopordon laconicum
Aerial part AR No medical use has been reported for this species. [114] Onopordon sibthorpianum Aerial part AR No medical use has been reported for this species. [114] Convolvulaceae Ipomoea cairica Whole plant AR No medical use has been reported for this species. [42] Linaceae Linum usitatissimum Seed AR Traditionally been used for the management of [115] diarrhea and gastrointestinal infections.
(To be continued) [116] Forsythia koreana Fruit Arctiin, AR Forsythia fruits from the three species are known [25, 33] in China, Korea, and Japan as an anti-inflammatory, diuretics, antidote, and anti-bacteria medicine in traditional herbal medicine.
Forsythia suspense
Fruit AR (0.36%) [25] Forsythia viridissima Fruit, flower Arctiin, AR [8, 116, 117] Styracaceae Styrax japonica Stem bark Arctiin The stem bark has been used to treat inflammatory [118] diseases. Taxaceae Torreya nucifera Bark Arctiin, AR The fruits are widely used in folk medicine for the [119] treatment of tapeworm infestation in Korea.
Torreya jackii
Leaves AR No medical use has been reported for this species. [120] Thymelaeaceae Wikstroemia indica Whole plant AR (0.06%) Has long been employed as an antipyretic, detoxicant, [121] expectorant, vermifuge, and abortifacient agent in clinical practice in China. [30] inflammation suppression of IκBα phosphorylation and p65 nuclear translocation 0.01 to 1 μmol/L NR Decrease of TNF-α production and mRNA [36] level; inhibition of binding between AP-1 and its consensus oligonucleotide; inhibition of phosphorylation and activation of MAPKs 0.1 to 10 μmol/L Inhibition of NO and PGE 2 Reduction of iNOS and COX-2 expression; [33] production inhibition of NF-κB expression and binding; Suppression of phosphorylation of IκB, IKK and activation of MAPKs 0.3 to 32 μmol/L Inhibition of NO production Inhibition of TNF-α production [22] 10 to 50 μmol/L Inhibition of iNOS activity; slight Suppression of iNOS expression, IL-1β and [4] inhibition on COX-2 activity IL-6 gene expression; reduction of phosphorylation and nucleus translocation of JAK, STAT1 and STAT3 50 μmol/L Inhibition of iNOS activity Suppression of iNOS expression; promotion of [32] ubiqitination and degradation of iNOS by CHIP-associated proteasomes 3 to 100 μmol/L Inhibition of iNOS activity; no Suppression of iNOS expression; inhibition of [31] inhibition of COX-2 activity TNF-α and IL-6 production U937 1 to 16 μmol/L NR Inhibition of TNF-α production [22] Mice peritoneal 10 to 20 μmol/L NR Decrease of IL-1β, IL-6, and TNF-α level with [2] macrophage increased IL-10 and CD204; inhibition of NF-κB activation and p65 nuclear translocation; suppression of PI3K and AKT phosphorylation Silica-induced RAW264.7 0.1 to 10 μmol/L Inhibition of ROS production NR [25] inflammation Concanavalin Mice primary 0.5 to 16 μmol/L Inhibition of T cell and B cell NR [22] A and LPS splenocyte proliferation induced proliferation (To be continued) 791 www.chinaphar.com Gao Q et al Acta Pharmacologica Sinica various disease models, including local edema, colitis, acute lung injury, and brain trauma. AR was effective in relieving symptoms such as writhing response, capillary permeability accentuation, and edema volume in local tissue inflammation of rats induced by various stimulators [25] . Protective effects of AR against LPS-induced acute lung injury through suppression of MAPK, HO-1, and iNOS signaling was observed [26, 27] . Furthermore, AR reduced the infiltration of leukocytes into [25] acid-induced painting, single tissue MPO and EPO activities ear edema dose CarrageenanRats 10, 30, 100 mg/kg, Decrease of paw edema volumn NR [25] induced paw po, single dose edema LPS-Induced Rats 30, 100 mg/kg, iv, Reduced histological damage, Decrease of TNF-α, IL-1β, and IL-6 levels; [37] acute lung single dose myeloperoxidase activity, and down-regulation of NF-κB and p65 expression; injury wet-to-dry weight ratio of lung activation of AMPKα tissues Mice 50 mg/kg, ip, Decreased infiltration of Significantly reduction of NO production and iNOS [27] single dose inflammatory cells into BALF; expression; enhancement of heme oxygenase-1 production of pro-inflammatory expression, and decrease of MAPKs phosphorylation cytokines; reduced the malondialdehyde level; increased superoxide dismutase and catalase activities and glutathione peroxidase/glutathione disulfide ratio in the lung LPS-induced Mice 5 mg/kg, ip, NR Suppression of blood IL-1β and TNF-α level [2] colitis single dose TNBS-induced colitis Mice 30, 60 mg/kg, po, Reduced loss of body weight, Inhibition of IL-1β, TNF-α and IL-6 expression and [2] qd, 3 days colon shortening, macroscopic increase of IL-10 and CD204 expression; inhibition scores and MPO activity of NF-κB activation, as well as PI3K, AKT [2, 26, 28] . In addition, AR reduced brain water content and hematoma and accelerated wound closure in convection-enhanced delivery induced brain injury in mice through regulation of various inflammatory factors and numbers of MPO-positive cells [28] . The anti-inflammatory effect of AR was first shown to be mediated through the suppression of NO production via inhibition of inducible nitric oxide synthase (iNOS) at both the expression and activity levels. These findings have been confirmed in multiple in vitro studies that were primarily conducted on a lipopolysaccharide (LPS)-induced inflammatory model of RAW264.7 cells [22, [29] [30] [31] [32] , an immortalized murine macrophage cell line, and on U937 cells [22] , a human pro-macrophage cell line. The modulatory effects of AR on cyclooxygenase-2 (Cox-2) [31, 33] have also been reported, but there is controversy regarding the effect of AR on Cox-2. Although both studies were carried out on the same LPSinduced RAW 267.4 cells, Zhao et al reported that AR did not affect Cox-2 expression or enzyme activity at 3-100 µmol/L [31] , whereas Lee et al found that 0.1 µmol/L of AR could decrease COX-2 expression and PGE 2 production by 26.70%±4.61% and 32.84%±6.51%, respectively [33] . Other in vitro anti-inflammatory effects of AR include inhibition of LPS-induced primary murine splenocyte proliferation [22] , inhibition of anti-CD3/CD28 antibody-induced primary human T lymphocyte proliferation [3] , and polarization of M1 macrophages to M2-like macrophages [2] . The anti-inflammatory effect was also confirmed on silica-induced and peptidoglycan-induced inflammatory cell models [25] . In addition, AR was reported to have immunomodulatory effects towards type I-IV allergic inflammation [34] , as well as inhibiting mast cellmediated allergic responses [35] . Molecular mechanisms accounting for the anti-inflammatory effect of AR have been widely investigated in the past decade. Generally, upon sensing infection or tissue damage, transcription factors such as nuclear factor κB (NF-κB) are activated to induce the expression of genes participating in the inflammatory response (eg, iNOS and COX-2). Cytokine-mediated feed-forward loops can amplify and coordinate this inflammatory response [15] . The anti-inflammatory effect of AR has been attributed to its potent in vitro and in vivo modulating effects on several important cytokines, such as tumor necrosis factor-α (TNF-α) [2, 22, 26, 28, 31, 36, 37] , interleukin-6 (IL-6) [2, 26, 28, 29, 31, 37] , interleukin-1β (IL-1β) [2, 29, 37] , and interleukin-10 (IL-10) [2, 28] . Inhibitory effects of AR on the expression levels of other cytokines, such as interleukin-2 and interferon-γ (IFN-γ), were also found in vitro [3] . Multiple upstream mechanisms for the modulating effect of AR on cytokines were proposed. Both in vivo and in vitro studies showed that AR inactivated NF-kB by inhibiting p65 nuclear translocation, suppressing I-κ phosphorylation [2, 26, 30, 37] , suppressing phosphorylation of mitogen-activated protein kinases (MAPKs) [26, 36] , and inhibiting phosphorylation of phosphatidylinositide 3-kinases (PI3K) and protein kinase B (AKT) [2, 26] . Other proposed mechanisms include suppression of the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway [4, 29] , promotion of degradation of iNOS synthase through the carboxyl terminus of Hsc70-interacting protein (CHIP)-associated proteasome [32] , and activation of adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPKα) [37] . However, there are few studies on the anti-inflammatory effects of arctiin. In three studies, arctiin was reported to have similar anti-inflammatory effects to those of AR in vitro and in vivo [33, 38, 39] .
Effect of AR and arctiin against exogenous pathogens AR, arctiin, and A lappa also demonstrated inhibitory effects on microorganism (Table 3) , including viruses and bacteria, common exogenous stimuli for inflammatory responses. Studies attributed the anti-viral effects of A lappa to the major component AR. AR was reported to have strong anti-viral activities against influenza A in both in vitro and in vivo settings, and the mechanism of the anti-influenza effect of AR was related to the direct inhibitory effect on viral replication [5, 6, 40] . Furthermore, protective effects of AR against more lethal pathogens, such as human immunodeficiency virus and Japanese encephalitis virus, were also reported with in vitro and in vivo models [7, [41] [42] [43] . AR demonstrated inhibitory effects on the bacteria Helicobacter pylori, but this effect was not sufficient to attenuate the gastric carcinogenesis in Mongolian gerbils [44] . Other anti-bacterial activities of A lappa against pathogens such as Escherichia coli and Pseudomonas aeruginosa were all demonstrated using the extract of the herb on in vitro disk diffusion models [45] [46] [47] [48] . In addition, inhibitory effects of A lappa on other microorganisms, such as fungi, were also demonstrated [46] . However, whether these effects are attributed to AR and arctiin is still unclear.
Anti-inflammatory activities of AR and arctiin on chronic diseases
AR and arctiin have also been associated with beneficial effects on some chronic diseases, such as metabolic disorders and central nervous system dysfunctions, partially due to their anti-inflammatory activity. AR and arctiin demonstrated their effects on ameliorating metabolic disorders in various cell lines [49] [50] [51] , ob/ob mice, and streptozotoxin (SZT)-induced diabetic rats [8] [9] [10] . Neuroprotective effects of AR were demonstrated on cultured neuron cells, cerebral ischemia rats, memory deficit mice, experimental autoimmune encephalomyelitis in mice, Aβ-induced AD mice, and transgenic Alzheimer's disease mice [11-13, 52, 53] . Multiple mechanisms for these neuroprotective effects were proposed, including scavenging free radicals, down-regulating pro-inflammatory cytokines, regulating AMPK and PPAR-γ/ROR-γt signaling, reducing Tau hyperphosphorylation and inhibiting Aβ production [11] [12] [13] [52] [53] [54] . In addition, although AR and A lappa demonstrated their potential anti-cancer activities on various cancer cell lines, there is still a lack of sufficient evidence for their anti-cancer activities on in vivo models [21, [55] [56] [57] [58] [59] . In summary, AR was reported as the most potent bioactive component of A lappa in the majority of studies, while the bioactivities of arctiin were lower than those of AR in most Human AR HTLV-III B/H9-Jurkat 0.5 µmol/L The expression and reverse transcriptase activity of HIV-1 [42] immunodeficiency cell system proteins p17 and p24, was inhibited by AR. virus (HIV) AR 3'-processing and 100 µmol/L AR suppressed the integration of proviral DNA into the cellular [43] integration assays DNA genome but was inactive in the cleavage (3'-processing) and integration (strand transfer) assays. AR CHME5 cells 5-20 µmol/L AR regulated the upstream PI3K enzyme to abolish the [7] cytoprotective phenotype of HIV virus type 1 Tat-expressing CHME5 cells. Influenza A Arctiin BALB/c mice 5 mg/d, po Lethal infection was decreased, virus production was reduced, [5] antibody response was elevated by treatment of arctiin. AR NIH mice 10, 100 µg/kg, po Lung consolidation due to viral infection was significantly inhibited [6] by AR. Survival time of infected mice was prolonged by AR treatment. AR MDCK cells 5, 25, 50 µmol/L IC 50 of AR were 3.8 µmol/L and 2.9 µmol/L in plaque yield [5] reduction assay. Synergistic effect of AR with oseltamivir was found. AR Hemagglutination titer 6.7-53.6 µmol/L Hemagglutination titer was inhibited, indicating direct inhibitory [40] effect against influenza virus replication of AR.
Helicobacter pylori AR
Mongolian gerbil 10 μmol/L, 0.1% AR showed inhibitory effect of H. pylori colonies at 10 μmol/L, but [44] in diet failed to attenuate neoplasia in vivo. porcine circovirus AR Mice 200 μg/kg, ip Significant inhibition of PCV2 proliferation in the lungs, spleens [124] type 2 and inguinal lymph nodes.
Abbreviation: ip: intraperitoneal injection; po: oral administration.
reports evaluating both compounds. AR demonstrated potent effects on inflammatory responses. The anti-inflammatory effect of AR may function synergistically with its anti-viral effect to manage some infectious conditions. However, inflammatory responses also have a role in the progression of several chronic diseases, and AR may serve as an auxiliary treatment for these chronic diseases, including metabolic disorders and central nervous system dysfunctions.
Pharmacokinetic properties of AR and arctiin
Despite the research attention AR has received due to its promising therapeutic potential, biopharmaceutic and pharmacokinetic investigations of AR and arctiin are rare. In this section, we will discuss the pharmacokinetic properties of arctiin and AR, including the absorption, distribution, metabolism and excretion characteristics, focusing on the biotransformation of arctiin and AR. Furthermore, comparison will be made among the pharmacokinetic profiles of AR after various routes of administration.
Pharmacokinetic properties of arctiin AR was regarded as the only metabolite in most in vivo pharmacokinetic studies of arctiin, due to its much higher concentration in plasma compared with that of arctiin [5, 60] . However, in vitro incubation studies of arctiin or AR with intestinal content or feces revealed that intestinal microbiota mediated the biotransformation of arctiin to AR in the intestine [61, 62] , followed by demethylation and a series of other biotransformation processes leading to the formation of enterolactone (3) [63] [64] [65] . Wang et al reported three metabolites in rat urine and feces after oral administration of 30 mg/kg arctiin (1), including AR (2), enterolactone (3) and (2R,3R)-2-(3′-hydroxybenzyl)-3-(3″,4″-dimethoxybenzyl)-butyrolactone, an intermediate metabolite [66] ( Figure 2 ).
Pharmacokinetic properties of AR
The pharmacokinetic properties of AR are summarized in Table 4 . After oral ingestion, efficient absorption of AR was demonstrated in a Caco-2 cell monolayer transport study and a rat in situ intestinal perfusion model [67, 68] . The duodenum was found to be the best absorption segment of AR among all the intestinal segments [67] . Although the Caco-2 cell monolayer model showed that no significantly active efflux was involved during the absorption of AR, with an efflux ratio of 1.17 [68] , an in situ intestinal perfusion model showed that absorption of AR in the duodenum was significantly improved by co-treatment with the P-glycoprotein (P-gp) inhibitor verapamil [67] , suggesting AR is a potential P-gp substrate. After entering the systemic circulation, AR exhibited a strong binding capacity (99.8%-100%) to plasma. The high plasma binding was found in various species, including human, beagle dog, and rat [69] . The tissue distribution of AR was only investigated after hypodermic or oral administration to rats. After hypodermic injection of 0.806 µmol/kg AR to rats, the AR concentrations were reduced at 6 h to approximately 1/10 of their peak values at 0.25 h in most organs, indicating no accumulation in tissues, and the peak concentration of AR was in the intestine, followed by the heart, liver, pancreas, and kidney [69] . After oral administration of 70 mg/kg AR to rats, the tissue concentration of AR peaked at 30 min and was quickly eliminated within 4 h, and the concentration of AR was highest in the spleen, followed by the liver and the other organs [70] . AR was eliminated via extensive metabolism to various metabolites. The dominant metabolic pathways of AR are summarized in Figure 2 . In vitro incubation of AR with the intestinal microbiota demonstrated that similar to acrtiin, AR can be biotransformed into a series of demethylation and dehydroxylation products, such as 3'-demethylarctigenin, 3'-demethyl-4'-dehydroxyarctigenin, and eventually to the enterolactone (3) anaerobically within 24 h [61, 65, 71] . In rats, extensive first-pass metabolism of AR occurred in both the intestine and liver, with the formation of two major in vivo metabolites, namely, arctigenic acid (4) and arctigenin-4'-Oglucuronide (5) [68, [72] [73] [74] . Further in vitro and clinical studies confirmed that similar biotransformation also occurred in humans. The hydrolysis of AR was mediated by human paraoxonase 1 in plasma [73] , and glucuronidation of AR was mediated by UGT1A9, UGT2B7 and UGT2B17 in the liver and intestine [74] . A phase I clinical trial of the herbal product GBS-01 on pancreatic cancer patients demonstrated that after oral administration of GBS-01 at a dose of 12 g AR per person, the area under the plasma concentration versus time curve (AUC) of arctigenin-glucuronide was almost 1000 times higher than that of AR [75] . Notably, the extent of metabolism of AR might be different between species. As reported by Li et al, approximately 62%, 3.7%, 25.9% and 15.7% of the AR remained after incubation in human, monkey, dog, and rat liver microsomes for 90 min [69] . Other minor in vivo metabolites found in SD rats include 4-O-demethylarctigenin, arctigenin 4-O'-sulfate, arctigenic acid-4'-O-glucuronide, and 4-O-demethyl-arctigenin-4,4'-O-di-glucuronide [72, 73] . Following rapid formation, fast elimination of the two major metabolites was observed after both intravenous and oral administration of AR to rats. Several glucuronidation products of AR, including arctigenin-4'-O-glucuronide (5), were excreted via bile, with potential enterohepatic circulation suggested [72] . These complex metabolic pathways of AR were described and verified by an integrated semi-mechanistic pharmacokinetic model of rats [72] and warrant further verification in human trials.
Due to the extensive first-pass metabolism of AR, it is likely that most AR, either as single compound or as active component in herbal preparations, would be quickly metabolized after oral administration. As shown in Table 5 , after oral administration, the plasma concentrations of AR were very low and even undetectable in various animal models, sug- Table 4 . Summary of absorption, distribution, metabolism and elimination of AR.
Model Dose Findings Ref

Absorption
Caco-2 cell monolayer 50 μg/mL AR efficiently passed through the cell monolayer with P app of (1.76±0.48)×10 -5 (apical to [68] basolateral) and (1.50±0.61)×10 -5 (basolateral to apical).
In situ SD rat intestinal 25 μg/mL Efficient absorption of AR was observed with extensive intestinal first-pass metabolism demonstrated. [68] perfusion model In situ intestinal 5, 10, 20 μg/mL AR belongs to easily absorbed agents. Duodenum was the best absorption segment of AR. The P eff and [67] perfusion on normal K a of AR were increased by 60% and 52% in duodenum with co-treatment of verapamil. The absorption and diabetic SD rats of AR was promoted in diabetic rats. Distribution In vitro plasma 0.0672, 0.269, AR exhibited a strong binding capacity (99.8%-100%) with plasma, including human, beagle dog, and [69] incubation 1.075 μmol/L rat. Wistar rat 0.806 μmol/kg, AR concentration in the intestine was the highest, followed by heart, liver, pancreas, and kidney. [69] ih No accumulation of AR in tissues after 6 h. SD rat 30, 50, AR was rapidly distributed into organs, and C max in tissues was observed at 30 min. The content of [70] 70 mg/kg, po AR in spleen was the highest.
Metabolism and elimination
Human fecal inoculum 0.2 to Three metabolites of AR were identified under anaerobic condition: enterolactone (3), [65] incubation 0.35 mmol/L 3'-demethyl-4'-dehydroxyarctigenin and 3'-demethylarctigenin. Eubacterium ARC-2 0.6 mmol/L After 24-h incubation, AR was transformed to 4', 4'-dihydroxylenterolatone through 3 types of [61, 71] incubation demethylation products under anaerobic condition.
Rat intestinal content
After 4-h incubation, AR was stable in rat small and large intestinal content solution, while arctigenic [72] solution acid was converted back to arctigenin in rat large intestinal content. All three glucuronides, were hydrolysed back to corresponding parent compounds. In situ SD rat intestinal 25 μg/mL Extensive intestinal first-pass metabolism of AR to arctigenic acid (4) and arctigenin-4'-O-glucuronide [68] perfusion model (5) was identified. Human recombinant 0.27 to Paraoxonase 1 was confirmed to be the enzyme responsible for AR hydrolysis. [73] paraoxonase 1 134.4 μmol/L V79 Chinese hamster 1 mmol/L AR was converted to 3'-demethyl-arctigenin in cells expressing rat Cyp2b1. [125] cells with rat Cyp2b1 Rat liver/intestine 0.269 to Extensive glucuronidation of AR was observed in both liver and intestine microsome. No [72] microsome 67.2 μmol/L further glucuronidation or demethylation of arctigenic acid (4) in liver and intestine microsome. Rat liver cytosol 10 nmol/L 3'-Demethyl-arctigenin was converted back to AR. [126] incubation Human liver/intestine 100 μmol/L AR was metabolized to 4′-O-glucuronide (5) in human liver and intestinal microsome mainly via [74] microsomes UGT1A9, UGT2B7 and UGT2B17. Human, monkey, dog, 100 μmol/L Around 62%, 3.7%, 25.9% and 15.7% of AR remained after incubated in human, monkey, dog, and [69] and rat liver microsome rat liver microsome for 90 min. SD rats 3 mg/kg, po Arctigenic acid (4) and arctigenin-4'-O-glucuronide (5) was identified as major metabolites in rat [73] plasma after oral administration of AR. 4-O-demethylarctigenin was also identified in vivo. SD rats 0.48 to Rapid formation of arctigenic acid (4) and arctigenin-4'-O-glucuronide (5) with quick elimination of [72] 2.4 mg/kg, iv; both parent and metabolites were observed after both intravenous and oral administrations. No 2.4 to quantifiable AR was identified after oral administration due to extensive first-pass metabolism 12 mg/kg, po SD rats 0.96 mg/kg, iv Arctigenin-4'-O-glucuronide (5), arctigenic acid-4'-O-glucuronide, 4-O-demethyl-arctigenin [72] -4,4'-O-di-glucuronide, and trace amount of arctigenic acid (4) were found in bile at 0-15 min. Wistar rat 0.806 μmol/kg ih Within 72 h after drug-delivery, the urine accumulative excretion ratio was 1.93% and the excretory [69] amount of AR in faeces and bile were 0.248% and 0.182%, respectively.
Abbreviation: iv: intravenous administration; ih: hypodermic injection; po: oral administration.
gesting poor oral bioavailability. The pharmacokinetic profile of AR in humans after oral administration was investigated in a phase I clinical trial of the herbal product GBS-01. After oral administration of GBS-01 at a dose of 12 g AR per person, the peak concentration of AR in the plasma of the pancreatic cancer patients was 66.56±26.81 ng/mL, and the AUC was 487.97±368.86 ng*h/mL [75] . Given the low molecular weight of AR and its high permeability demonstrated in the absorption models, the poor oral bioavailability of AR should be mainly due to its extensive first-pass metabolism rather than limita-tions of membrane permeability. Thus, delivering AR through alternative administration routes might be plausible to bypass the first-pass metabolism and improve its bioactivities. Alternative routes for administration of AR, including hypodermic injection and sublingual administration, were tested on experimental animals. The results demonstrated substantially improved AUC and bioavailability of AR after hypodermic or sublingual administration compared with that from the oral administration (Table 5 ) [69] . These results suggested that optimization of the administration routes for AR may potentially improve its therapeutic efficacy by increasing the systemic and target organ exposure. Further pharmacokinetic/pharmacodynamic studies of AR after different routes of administration are warranted.
Clinical usages
As described previously, AR and arctiin served as marker compounds in the quality control of numerous proprietary Chinese medicines. Most of these products are for treatment of common cold, flu and related symptoms, such as various dosage forms of Yinqiaojiedu decoction [76] [77] [78] , Lingyang ganmao decoction [79, 80] and Fengreganmao granules [81, 82] . Despite its popularity, Fructus Arctii is not commonly used alone. Therefore, reports on the clinical trials of AR, arctiin or A lappa alone are rather limited. As summarized in Table 6 , only four clinical trials were identified for evaluation of the therapeutic effects of AR, arctiin or A lappa, with diverse indications. Despite their high Jadad scores (2 out of 3 received full score of 5) [83] , three randomized controlled trials demonstrating the efficacy of arctiin (0.5-1 g, t.i.d.) or Fructus Arctii (20 g, t.i.d.) against diabetic nephropathy were actually reported by the same group, with a similar study design and dose regiments [84] [85] [86] . A recent phase I clinical study co-sponsored by the Japanese National Institute for Cancer Research and Kracie Pharmaceutical Co, Ltd confirmed the safety of an oral product containing a high content of AR (GBS-01) (dose equal to 3 to 12 g daily) [75] . Moreover, a study protocol for evaluating A lappa-containing moisturizing cream for dry skin and itch relief in a randomized, double-blind, placebo-controlled trial was published [87] . Similarly, A lappa was also demonstrated to effectively treat acne vulgaris in a recent uncontrolled observational interventional study in India [88] . The anti-inflammatory effects of AR, arctiin or A lappa have not yet been confirmed in the clinic. Further randomized controlled trials are needed to evaluate the therapeutic efficacy of AR and arctiin.
Conclusions
Inflammatory responses are an important part of various acute and chronic disease conditions. AR, as the most potent bioactive component of A lappa with anti-inflammatory activities, is a promising therapeutic compound against acute inflammation as well as several chronic diseases. However, pharmacokinetic investigations suggested that the extensive firstpass metabolism of AR would hinder its in vivo and clinical efficacy after oral administration. To optimize the in vivo and clinical efficacy of AR, alternative administration routes other than oral administration are suggested. AR could be delivered through sublingual or buccal routes that allow rapid onset of the treatment of acute inflammation and influenza; transdermal routes for the treatment of skin conditions; and the intranasal route for targeting central nervous system dysfunctions. In addition, considering the extensive first-pass metabolism of AR and the higher plasma concentrations of metabolites compared with parent compound observed, the potential pharmacological effects of the metabolites of AR should be studied. Further reports with simultaneous monitoring of pharmacokinetics and pharmacological properties are essential for a better understanding of the effects of AR. 
